Related Experiment Videos
Rheumatoid arthritis exacerbation caused by exogenous interleukin-12
E Peeva1, A D Fishman, G Goddard
1Montefiore Medical Center, Bronx, New York 10467, USA.
Arthritis and Rheumatism
|February 29, 2000
Summary
Interleukin-12 (IL-12) cancer therapy can trigger severe rheumatoid arthritis (RA) flares. This case report highlights the first instance of exogenous IL-12 causing a significant RA exacerbation.
Area of Science:
- Immunology
- Oncology
- Rheumatology
Background:
- Interleukin-12 (IL-12) is a cytokine with known proinflammatory, immunoregulatory, and antitumor effects.
- IL-12 is critical for T-helper 1 (Th1) responses, interferon-gamma production, and cell-mediated cytotoxicity.
- IL-12 is being explored as an experimental cancer therapy.
Observation:
- Patients undergoing IL-12 therapy may experience adverse effects due to its immunomodulatory properties.
- Particular concern exists for individuals with T-cell mediated autoimmune diseases, such as rheumatoid arthritis (RA).
Findings:
- A case of severe rheumatoid arthritis exacerbation occurred in a patient treated with IL-12 for metastatic cervical cancer.
- This represents the first documented instance of exogenous IL-12 inducing a rheumatoid arthritis flare.
Implications:
- IL-12 therapy requires careful consideration in cancer patients with pre-existing autoimmune conditions like RA.
- Further research is needed to understand and manage the risks of IL-12 in immunocompromised patients with autoimmune comorbidities.